How does Selank work as an anxiolytic without sedation?

Selank inhibits enkephalinase enzymes that break down endogenous opioid peptides (Met-enkephalin, Leu-enkephalin), thereby elevating their synaptic concentration and prolonging their action at opioid µ- and δ-receptors. It also upregulates GABA-A receptor gene expression in hippocampus and amygdala through a genomic pathway, enhancing GABAergic tone without directly binding the benzodiazepine site. Because it does not directly potentiate all GABA-A receptor subtypes (including the sedating α1 subtype), it avoids the sedation and psychomotor impairment profile of classical anxiolytics.

What is enkephalinase inhibition?

Enkephalinases are proteolytic enzymes that cleave and inactivate Met-enkephalin and Leu-enkephalin — endogenous opioid peptides that modulate stress, pain, and anxiety. By inhibiting these enzymes (IC50 ~15 µM, Zozulya 2001), Selank slows enkephalin degradation, effectively increasing the available enkephalin concentration in the synapse. The mechanism is analogous to how ACE inhibitors raise bradykinin: not by directly stimulating the receptor, but by blocking the breakdown of the natural ligand.

Does Selank directly bind GABA-A receptors?

No. Selank's GABA-A effect is indirect and genomic — it upregulates GABA-A subunit gene expression in hippocampus and amygdala, which enhances the number or function of GABA-A receptors over time. It does not directly bind the GABA-A benzodiazepine site or potentiate the receptor channel acutely. This distinction explains why Selank lacks the immediate sedation of benzodiazepines and does not produce tolerance or withdrawal with repeated use in the published studies.

No. Selank does not directly bind opioid receptors at studied concentrations — it inhibits enkephalinases, the enzymes that degrade endogenous opioid peptides. The elevated enkephalins that result do act at opioid receptors, but Selank itself is not an exogenous opioid receptor agonist. It has no respiratory depression risk and no opioid receptor binding profile. The indirect elevation of endogenous enkephalins is mechanistically distinct from administering an exogenous opioid.

Has Selank's mechanism been confirmed in humans?

Partially. The clinical evidence is one Russian RCT (Zozulya 2008, PMID 18454096, n=62 GAD patients, 4 weeks) showing anxiety reduction comparable to medazepam without sedation. This confirms the functional anxiolytic outcome in humans. However, the specific enkephalinase inhibition mechanism has not been directly measured in human subjects — the IC50 data is from biochemical assays. No independent Western Phase 2/3 replication exists as of 2026.

Selank mechanism · enkephalinase inhibition · GABA-A · research use only

How Does Selank Work? The Enkephalin Mechanism Behind the Research

Selank (Thr-Lys-Pro-Arg-Pro-Gly-Pro) is a synthetic heptapeptide developed at the Institute of Molecular Genetics of the Russian Academy of Sciences. Its core sequence is derived from the immunomodulatory tetrapeptide tuftsin (Thr-Lys-Pro-Arg), extended by a C-terminal Pro-Gly-Pro stabilising tripeptide that significantly slows proteolytic degradation. The primary mechanism is indirect: Selank inhibits the enzymes (enkephalinases) that break down endogenous opioid peptides — Met-enkephalin and Leu-enkephalin — thereby elevating their synaptic concentration without directly activating opioid receptors itself. This enkephalin-preservation pathway produces the anxiolytic and anti-stress effects seen in preclinical models without the sedation or dependence associated with direct GABA-A modulators or conventional anxiolytics. This page explains each mechanism with the cited data. All information is general educational context about a research compound. Titan Peptide Lab supplies Selank for laboratory and research use only — not for human use, not as a drug or therapeutic product, not as medical advice.

Selank nasal spray — $59.99 (RUO)Semax + Selank stack — $105.00 (RUO)

What Selank actually is

Selank is a 7-amino-acid synthetic peptide (Thr-Lys-Pro-Arg-Pro-Gly-Pro) designed as a stable analogue of tuftsin, a naturally occurring immunomodulatory tetrapeptide found in the Fc region of IgG. The original tuftsin sequence (Thr-Lys-Pro-Arg) was modified by adding the C-terminal Pro-Gly-Pro extension, which was discovered to confer significant resistance to the aminopeptidases and endopeptidases that would otherwise rapidly degrade the peptide in plasma — extending the research window from minutes to hours. The LKKTET motif approach used in TB-500 is structurally different; Selank's stabilisation relies on the C-terminal tripeptide shield. The peptide was developed specifically for anxiolytic and nootropic research without the sedation and dependence profile of existing drugs.

Selank dosage reference →

Enkephalinase inhibition: the primary mechanism

Selank's primary described mechanism is inhibition of enkephalin-degrading enzymes — enkephalinases — the protease class that cleaves and inactivates Met-enkephalin and Leu-enkephalin in the synapse. Zozulya et al. 2001 (PMID 11550013) reported an IC50 of approximately 15 µM for Selank's enkephalinase inhibitory activity. By slowing the breakdown of endogenous enkephalins, Selank indirectly elevates their synaptic concentration, prolonging their action on opioid µ- and δ-receptors. This mechanism is analogous to how ACE inhibitors elevate bradykinin by blocking its degradation rather than directly stimulating bradykinin receptors. Importantly, Selank itself does not appear to directly bind opioid receptors at the concentrations studied — it is an indirect modulator.

Selank vs benzodiazepines comparison →

GABA-A gene expression: the secondary mechanism

In addition to the enkephalinase inhibition pathway, Selank has been shown to upregulate GABA-A receptor subunit gene expression in hippocampus and amygdala — brain regions central to fear and anxiety processing. This GABA-A effect is genomic (gene expression level), not direct receptor binding (in contrast to benzodiazepines, which directly potentiate GABA-A by binding the benzodiazepine site). The practical consequence is that Selank can enhance GABAergic tone without triggering the sedation, tolerance, or withdrawal profile associated with direct GABA-A modulators. Zozulya et al. 2008 (PMID 18454096) in a randomised study of 62 generalised anxiety disorder patients found Selank produced anxiety reduction comparable to medazepam (a benzodiazepine) without the sedation or psychomotor impairment.

Peptides for anxiety research →

BDNF normalization under stress

A third documented effect is BDNF modulation under chronic stress conditions. Kolik et al. 2019 (PMID 31625062) showed that Selank normalised stress-depleted BDNF levels in rodent chronic stress models. This BDNF effect complements the enkephalin pathway: chronic stress suppresses BDNF, which is associated with anxiety and depressive-like behaviour; Selank's ability to restore BDNF toward baseline offers a neuroplasticity mechanism alongside the acute anxiolytic enkephalin route. This places Selank in a similar mechanistic territory to antidepressants that work partly by raising BDNF — though through a different upstream pathway (enkephalin/opioid tone modulation vs monoamine reuptake inhibition).

Peptides for stress research →

Why Selank is non-sedating

The non-sedating profile of Selank versus conventional anxiolytics is mechanistically explainable. Benzodiazepines directly potentiate all GABA-A receptor subtypes, including α1-containing receptors in the brainstem and cerebellum that mediate sedation, motor impairment, and anterograde amnesia. Selank does not directly bind GABA-A; its GABA-A gene expression effect is indirect and regionally selective. The primary enkephalin pathway also lacks the broad CNS depressant activity of direct GABAergic drugs. In Zozulya 2008, no clinically significant sedation, psychomotor impairment, or withdrawal was observed across the 4-week study period — contrasting with the medazepam comparator arm.

Selank safety and tolerability data →

What the mechanism data doesn't establish

Selank's mechanistic data is real, but geographically concentrated and limited in scale. Zozulya 2001 (IC50 data) and Zozulya 2008 (the 62-patient RCT) are both Russian-authored. No independent Western Phase 2 or Phase 3 clinical trial has replicated the anxiolytic finding or measured the enkephalin mechanism in humans. The BDNF normalisation data (Kolik 2019) is from rodent chronic stress models. Selank received approval in Russia for anxiety treatment in the 2000s; it is not approved by the FDA or EMA. Titan supplies Selank as a research-use-only compound — the existing evidence does not constitute clinical validation for any use.

Selank regulatory information →

Three mechanisms — sourced and plain

Selank's mechanistic pathways: enkephalin preservation, GABA-A gene expression, and BDNF dynamics.

Each row covers one mechanism, the key source, and the caveat that applies. The enkephalinase inhibition pathway has the strongest direct experimental evidence.

Enkephalinase inhibition (primary): Selank inhibits Met- and Leu-enkephalin-degrading proteases in the synapse, elevating endogenous enkephalin tone. IC50 ~15 µM (Zozulya 2001, PMID 11550013). Indirect opioid-receptor modulation without direct receptor binding at studied concentrations.
GABA-A gene expression upregulation: Selank increases GABA-A receptor subunit gene expression in hippocampus and amygdala. Genomic (not direct binding), regionally selective. Explains anxiolytic profile without sedation/tolerance of direct GABA-A modulators (benzodiazepines).
BDNF normalization under chronic stress: Restores stress-depleted BDNF to near-baseline in rodent chronic stress models (Kolik 2019, PMID 31625062). Neuroplasticity mechanism complementing the acute enkephalin anxiolytic pathway. Rodent data only.
Human RCT evidence: Zozulya 2008 (PMID 18454096), n=62 GAD patients: Selank comparable to medazepam on anxiety reduction (HARS scale) over 4 weeks, without sedation/psychomotor impairment. Russian-authored, single study, no independent Western replication.
Structural stabilisation (Pro-Gly-Pro C-terminal): The Pro-Gly-Pro extension protects the tuftsin core sequence against rapid proteolysis, extending plasma residence from minutes (tuftsin) to hours (Selank). This is the modification that made intranasal delivery a viable research route.
Non-sedating vs benzodiazepines: mechanism: Benzodiazepines directly potentiate all GABA-A subtypes including sedating α1. Selank's GABA-A effect is indirect (gene expression) and regionally selective — avoids brainstem α1 flooding. No sedation in Zozulya 2008 human study; no withdrawal on cessation.

Questions researchers ask

Before you order.

How does Selank work as an anxiolytic without sedation?: Selank inhibits enkephalinase enzymes that break down endogenous opioid peptides (Met-enkephalin, Leu-enkephalin), thereby elevating their synaptic concentration and prolonging their action at opioid µ- and δ-receptors. It also upregulates GABA-A receptor gene expression in hippocampus and amygdala through a genomic pathway, enhancing GABAergic tone without directly binding the benzodiazepine site. Because it does not directly potentiate all GABA-A receptor subtypes (including the sedating α1 subtype), it avoids the sedation and psychomotor impairment profile of classical anxiolytics.
What is enkephalinase inhibition?: Enkephalinases are proteolytic enzymes that cleave and inactivate Met-enkephalin and Leu-enkephalin — endogenous opioid peptides that modulate stress, pain, and anxiety. By inhibiting these enzymes (IC50 ~15 µM, Zozulya 2001), Selank slows enkephalin degradation, effectively increasing the available enkephalin concentration in the synapse. The mechanism is analogous to how ACE inhibitors raise bradykinin: not by directly stimulating the receptor, but by blocking the breakdown of the natural ligand.
Does Selank directly bind GABA-A receptors?: No. Selank's GABA-A effect is indirect and genomic — it upregulates GABA-A subunit gene expression in hippocampus and amygdala, which enhances the number or function of GABA-A receptors over time. It does not directly bind the GABA-A benzodiazepine site or potentiate the receptor channel acutely. This distinction explains why Selank lacks the immediate sedation of benzodiazepines and does not produce tolerance or withdrawal with repeated use in the published studies.
Is Selank an opioid?: No. Selank does not directly bind opioid receptors at studied concentrations — it inhibits enkephalinases, the enzymes that degrade endogenous opioid peptides. The elevated enkephalins that result do act at opioid receptors, but Selank itself is not an exogenous opioid receptor agonist. It has no respiratory depression risk and no opioid receptor binding profile. The indirect elevation of endogenous enkephalins is mechanistically distinct from administering an exogenous opioid.
Has Selank's mechanism been confirmed in humans?: Partially. The clinical evidence is one Russian RCT (Zozulya 2008, PMID 18454096, n=62 GAD patients, 4 weeks) showing anxiety reduction comparable to medazepam without sedation. This confirms the functional anxiolytic outcome in humans. However, the specific enkephalinase inhibition mechanism has not been directly measured in human subjects — the IC50 data is from biochemical assays. No independent Western Phase 2/3 replication exists as of 2026.